Who owns GPCR? 13F holders and whale ownership
GPCR is tracked across public portfolios in Whale Analyzer. This page answers who owns GPCR, which top funds are buying GPCR, aggregate disclosed value, and recent position changes based on public data. Samuel Isaly is the largest reported holder at $71M; the top five funds control 100.0% of reported ownership; institutions were net buying last quarter (1 increased, 0 reduced); the stock trades above the aggregate whale cost basis of $18.15. Top tracked holders include Samuel Isaly, Baker Bros. Advisors, and Neil Shen.
Continue to the live GPCR dashboardTop holders
| Investor | Reported value | Shares | Change |
|---|---|---|---|
| Samuel Isaly 13F portfolio OrbiMed Advisors holdings | $71.1M | 1.5M | Increased |
| Baker Bros. Advisors 13F portfolio Baker Bros. Advisors holdings | $69.0M | 1.4M | Held |
| Neil Shen 13F portfolio HongShan (Sequoia China) holdings | $6.2M | 266.1K | Held |
Ownership concentration
Reported ownership of GPCR is highly concentrated across tracked institutions.
- Single largest holder: 48.6% of reported ownership
- Top 5 holders: 100.0%
- Top 10 holders: 100.0%
Whale activity this quarter
Across 3 tracked institutions, 2 held, 1 increased. Net positioning is net buying.
- Samuel Isaly — OrbiMed Advisors ($71.1M) (▲ 27.0% qoq shares) · avg cost $28.82
- Baker Bros. Advisors — Baker Bros. Advisors ($69.0M) (→ 0.0% qoq shares) · avg cost $7.16
- Neil Shen — HongShan (Sequoia China) ($6.2M) (→ 0.0% qoq shares)
Whale cost basis vs current price
The aggregate tracked cost basis is $18.15 versus a current price of $49.71, so GPCR trades above its cost basis (+173.9%). Average unrealized P&L across tracked holders: 221%.
Sector positioning — Health Care
GPCR sits within the Health Care sector alongside 221 other tracked names. Compare whale ownership across peers:
How to use this page
Values are reported public positions from tracked 13F filers and disclosures — not real-time ownership totals. Open the live GPCR dashboard for price charts and cross-investor scans, or read the SEC 13F guide.
Related stock holder pages
- EWTX whale holders — EDGEWISE THERAPEUTICS INC
- ELVN whale holders — ENLIVEN THERAPEUTICS INC
- LLY whale holders — ELI LILLY & CO
- SVA whale holders — SINOVAC BIOTECH LTD
- BSX whale holders — BOSTON SCIENTIFIC CORP
- SION whale holders — SIONNA THERAPEUTICS INC
- AZN whale holders — ASTRAZENECA PLC
- MYGN whale holders — MYRIAD GENETICS INC
Learn more in Whale Analyzer Academy
Deepen your read on GPCR with these Whale Analyzer Academy guides:
Frequently asked questions
Who owns GPCR stock?
Whale Analyzer tracks 3 public institutional holders of GPCR with a combined reported value of $146.4M. See the holder table above for the largest tracked positions.
Which top funds are buying GPCR?
Tracked institutions were net buying last quarter — 2 held, 1 increased. Check the "Change" column: "New" = fresh position, "Increased" = added, "Reduced" = trimmed.
How concentrated is GPCR ownership?
The top five tracked holders report 100.0% of aggregate ownership.
Is GPCR above or below the whale cost basis?
The aggregate tracked cost basis is $18.15 versus a current price of $49.71 (+173.9%).
What does 13F ownership mean for GPCR?
Use the interactive GPCR dashboard on Whale Analyzer for real-time holder analysis, or read our 13F Alpha Signals Guide.